O‘zbekiston кardiologiyasi Volume 2 Issue 3 (2025) · pp. 264-272

Early biomarkers of endothelial dysfunction: clinical implications for the diagnosis and management of cardiovascular disease

Нуриллаева, Н, Срожидинова, Н, Махкамова, М, Хафизова, Л., Nurillayeva, Nargiza, Srojidinova, Nigora, Maxkamova, Munisaxon, Xafizova, Lola, Nurillayeva, Nargiza, Srojidinova, Nigora, Makhkamova, Munisakhon, Khafizova, Lola

Read at source PDF

Abstract

This review synthesizes current evidence on early biomarkers of endothelial dysfunction (ED) in cardiovascular disease (CVD), emphasizing their role in diagnosis, prognosis, and management. ED, characterized by reduced nitric oxide bioavailability and increased inflammation, serves as a reversible precursor to atherosclerosis, thrombosis, and events like myocardial infarction. Established biomarkers, including adhesion molecules, cytokines, and inflammatory markers, reflect endothelial activation and predict CVD risk, with recent studies confirming their utility in hypertension. Emerging focus on L-arginine derivatives, particularly asymmetric dimethylarginine (ADMA), highlights its specificity as an endogenous nitric oxide synthase inhibitor, associated with vascular impairment in hypertension, diabetes, and CVD. Clinical trials, such as the AtheroGene and Framingham Offspring studies, demonstrate ADMA’s prognostic value for major adverse events. Future directions advocate integrating ADMA into multi-biomarker panels with AI and omics for personalized medicine, addressing gaps in standardization and early detection. Non-invasive techniques like flow-mediated dilation and ultrasound-derived markers complement biomarkers for subclinical CVD assessment. Overall, biomarker-driven strategies promise enhanced CVD prevention and tailored therapies.

endothelial dysfunctionasymmetric dimethylargininehomeostasisnitric oxidebiomarkerэндотелиальная дисфункцияасимметричный диметиларгинингомеостазоксид азотабиомаркер

Metadata source: the journal's OAI-PMH archive · Sindex does not store the full text; it links to the source.

Cite

APA 7 
Нуриллаева, Н, Срожидинова, Н, Махкамова, М, Хафизова, Л., Nurillayeva, Nargiza, Srojidinova, Nigora, Maxkamova, Munisaxon, Xafizova, Lola, Nurillayeva, Nargiza, Srojidinova, Nigora, Makhkamova, Munisakhon & Khafizova, Lola (2025). Early biomarkers of endothelial dysfunction: clinical implications for the diagnosis and management of cardiovascular disease. O‘zbekiston кardiologiyasi, 2(3), 264-272.
GOST R 7.0.5 
Нуриллаева, Н, Срожидинова, Н, Махкамова, М, Хафизова, Л., Nurillayeva, Nargiza, Srojidinova, Nigora, Maxkamova, Munisaxon, Xafizova, Lola, Nurillayeva, Nargiza, Srojidinova, Nigora, Makhkamova, Munisakhon, Khafizova, Lola Early biomarkers of endothelial dysfunction: clinical implications for the diagnosis and management of cardiovascular disease // O‘zbekiston кardiologiyasi. 2025. Т. 2. № 3. С. 264-272.
BibTeX 
@article{н2025,
  author  = {Нуриллаева, Н and Срожидинова, Н and Махкамова, М and Хафизова, Л. and Nurillayeva, Nargiza and Srojidinova, Nigora and Maxkamova, Munisaxon and Xafizova, Lola and Nurillayeva, Nargiza and Srojidinova, Nigora and Makhkamova, Munisakhon and Khafizova, Lola},
  title   = {Early biomarkers of endothelial dysfunction: clinical implications for the diagnosis and management of cardiovascular disease},
  journal = {O‘zbekiston кardiologiyasi},
  year    = {2025},
  volume  = {2},
  number  = {3},
  pages   = {264-272}
}
RIS 
TY  - JOUR
AU  - Нуриллаева, Н
AU  - Срожидинова, Н
AU  - Махкамова, М
AU  - Хафизова, Л.
AU  - Nurillayeva, Nargiza
AU  - Srojidinova, Nigora
AU  - Maxkamova, Munisaxon
AU  - Xafizova, Lola
AU  - Nurillayeva, Nargiza
AU  - Srojidinova, Nigora
AU  - Makhkamova, Munisakhon
AU  - Khafizova, Lola
TI  - Early biomarkers of endothelial dysfunction: clinical implications for the diagnosis and management of cardiovascular disease
JO  - O‘zbekiston кardiologiyasi
PY  - 2025
VL  - 2
IS  - 3
SP  - 264
EP  - 272
ER  -